Eli Lilly and Company is sponsoring the research. We are particularly excited about this research study because of the possibility that one compound could help prevent osteoporosis and heart disease in postmenopausal women and not put them at risk for breast or uterine cancer. Qualified participants should be aged 55 or older, have coronary disease or be at high risk for its occurrence, and should not have been on hormone replacement therapy for at least six months.
Heart disease is the leading killer of women in America and other developed nations.
All exams, tests and medications associated with the study will be provided at no cost. Parking at the 1525 Building is convenient and will also be provided at no cost. All Rights Reserved.